Other (Sugar alcohol), Small molecule/metabolite, Precursor to: Inositol phosphate secondary messengers, phosphatidylinositol lipids, Not a receptor, enzyme, transporter, or transcription factor
01
Overview
Myo-inositol is the most stable isomer of inositol, a six-carbon cyclic sugar alcohol and a polyol (C6H12O6) found in all living cells. It is highly water-soluble and acts primarily as the structural basis for many crucial secondary messengers in eukaryotic cells, particularly inositol phosphates and lipid-derived messengers such as phosphatidylinositol and its phosphorylated derivatives (PIP lipids). These inositol-containing molecules play a pivotal role in cellular signaling, energy metabolism, membrane structure, and are involved in diverse processes such as insulin signal transduction, cell growth, apoptosis, and neurotransmission. While inositol itself is not a direct pharmacological target, enzymes involved in its metabolism (e.g., inositol monophosphatase targeted by lithium) and signaling derivatives are clinically relevant.
As a precursor: mechanism involves metabolism to signaling lipids and messengers.
For *lithium*: inhibits inositol monophosphatase, reducing availability of free inositol and modulating signal transduction
03
Biological functions
Structural component of cell membrane phospholipids (phosphatidylinositol)Precursor to inositol phosphates (secondary messengers in signal transduction)Involved in lipid signaling cascadesPlays roles in insulin signaling, cytoskeleton assembly, nerve guidance, membrane potentials, serotonin activity, fat metabolism, and cholesterol reductionRequired for cell signaling, energy processing, and various cellular functions
04
Disease associations
Indirect roles implicated in:Cancer (via cell signaling)Neurodegenerative diseases (Alzheimer’s disease, Huntington’s disease, bipolar disorder, ALS, via inositol depletion and phosphoinositide signaling modulation)Metabolic disorders (diabetes, obesity via insulin signaling and energy sensing)Other disease relevance is through dysregulation of pathways that utilize inositol derivatives
05
Safety considerations
Notable safety concerns limited as it is generally regarded as safe and is found endogenouslyOveruse or misregulation implicated only indirectly via metabolic disorders and excessive signal transductionLithium toxicity involves inositol depletion but is not directly a safety issue of inositol supplementation
06
Interacting drugs
Lithium (inhibits inositol monophosphatase; basis of inositol depletion hypothesis)
1 more in the full profile.
07
Biomarkers
Not directly used as a biomarker; inositol/phosphatidylinositol and derivatives may be measured in disease contexts (e.g., psychiatric, neurodegenerative disorders, metabolic status)
Beyond the preview
Go deeper on Myo-inositol (MI).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myo-inositol (MI).